Peptides have become an important part of medical weight loss. Treatments like semaglutide and tirzepatide have shown substantial results in clinical trials, attracting interest from people exploring ways to manage their weight.
But with so many peptides being discussed, it can be difficult to understand which ones work, how they differ, and what the research actually says.
Some peptides have been studied extensively and approved for weight management. Others are still being researched for their potential effects on appetite, metabolism, and body composition.
Semaglutide, tirzepatide, and liraglutide are among the peptide-based medications with established evidence for weight loss. Tirzepatide has produced greater average weight loss than semaglutide in a direct clinical trial, while other peptides, including retatrutide, continue to attract research interest.
Understanding the differences can help you explore your options and make informed decisions with a healthcare provider.
What Are Peptides for Weight Loss?
Peptides are short chains of amino acids, the building blocks of proteins. They occur naturally in the body and are involved in several functions, including appetite regulation, digestion, and hormone signaling.
Some peptide-based medications are designed to mimic or activate hormones involved in these processes.
For example, glucagon-like peptide-1 (GLP-1) is a hormone released by the intestines after eating. It helps regulate blood sugar, slows stomach emptying, and sends signals that promote fullness.
Medications that activate GLP-1 receptors can reduce appetite and help people consume fewer calories.
Other peptides act on additional hormone pathways, which researchers are studying for their potential effects on metabolism and body composition.
However, peptides have different biological functions. Their effectiveness for weight loss depends on how they work and what clinical research has demonstrated.
Which Peptides Are Most Effective for Weight Loss?
Several peptide-based treatments have been studied for weight management, although the strength of evidence varies. Semaglutide, tirzepatide, and liraglutide have established clinical evidence and FDA-approved weight-management formulations.
1. Semaglutide
Semaglutide is a GLP-1 receptor agonist. It mimics the effects of the GLP-1 hormone, helping regulate appetite, food intake, and blood sugar. It is the active ingredient in medications such as Wegovy and Ozempic.
While both contain semaglutide, they have different approved uses. Wegovy is approved for chronic weight management in eligible patients, while Ozempic is primarily used for type 2 diabetes and certain related health risks.
Semaglutide is available in weekly injectable formulations and an approved oral weight-management formulation.
How effective is semaglutide for weight loss?
In a clinical trial involving 1,961 adults with overweight or obesity who did not have diabetes, researchers studied the effects of weekly semaglutide over 68 weeks.
Participants receiving semaglutide 2.4 mg alongside lifestyle support lost an average of 14.9% of their body weight.
Those receiving a placebo lost an average of 2.4%.
Approximately 86% of participants receiving semaglutide achieved at least 5% weight loss, while about half lost 15% or more.
These findings demonstrate how semaglutide can support meaningful weight reduction when used as part of a medical weight-management program.
Potential benefits of semaglutide
- Helps regulate appetite and reduce food intake.
- Supports significant weight loss in eligible patients.
- Can improve certain weight-related health measures.
- Has extensive clinical research supporting its effectiveness.
- Offers weekly injectable and oral treatment options.
Possible side effects and considerations
Common side effects include nausea, vomiting, diarrhea, constipation, and abdominal discomfort. Some patients experience these symptoms more frequently when beginning treatment or increasing their dose. Semaglutide also carries important warnings and contraindications. A healthcare provider should review medical history and treatment suitability before prescribing it.
2. Tirzepatide
Tirzepatide is another peptide-based medication with strong clinical evidence for weight loss. Unlike semaglutide, which targets GLP-1 receptors, tirzepatide activates two hormone receptors:
- GLP-1 (glucagon-like peptide-1)
- GIP (glucose-dependent insulinotropic polypeptide)
These hormones influence appetite, food intake, and blood sugar regulation. Tirzepatide is the active ingredient in Zepbound and Mounjaro. Zepbound is approved for chronic weight management in eligible adults, while Mounjaro is approved for type 2 diabetes.
How effective is tirzepatide for weight loss?
A 2025 clinical trial involving 751 adults with obesity who did not have diabetes directly compared tirzepatide and injectable semaglutide.
After 72 weeks:
- Participants taking tirzepatide lost an average of 20.2% of their body weight.
- Participants taking semaglutide lost an average of 13.7%.
Tirzepatide also produced greater average reductions in waist circumference. The findings suggest that tirzepatide can produce greater average weight loss than the injectable semaglutide regimens evaluated in the study.
However, individual responses vary, and treatment suitability depends on more than weight-loss results.
Potential benefits of tirzepatide
- Targets both GLP-1 and GIP hormone pathways.
- Helps regulate appetite and food intake.
- Has demonstrated substantial weight reduction in clinical trials.
- Requires once-weekly administration.
- Has shown greater average weight loss than injectable semaglutide in direct research.
Possible side effects and considerations
Tirzepatide can cause nausea, vomiting, diarrhea, constipation, and other gastrointestinal symptoms. Like semaglutide, it carries important warnings and may not be appropriate for everyone. Your healthcare provider can evaluate its potential benefits alongside your medical history, treatment goals, and possible side effects.
3. Liraglutide
Liraglutide is an earlier GLP-1 receptor agonist used for weight management. It works by activating GLP-1 receptors, helping regulate appetite and reduce food intake. Saxenda, which contains liraglutide, is FDA-approved for chronic weight management in eligible patients.
Unlike semaglutide and tirzepatide injections, which are commonly administered weekly, liraglutide requires daily injections.
How effective is liraglutide for weight loss?
Liraglutide has demonstrated meaningful weight-loss benefits in clinical studies. However, research comparing liraglutide with semaglutide suggests that semaglutide generally produces greater average weight reduction. In one clinical trial involving adults with overweight or obesity who did not have diabetes, researchers compared weekly semaglutide with daily liraglutide.
After 68 weeks:
- Participants receiving semaglutide lost an average of 15.8% of their body weight.
- Participants receiving liraglutide lost an average of 6.4%.
These findings illustrate how treatment effectiveness can differ even among medications that target the same hormone pathway.
Potential benefits of liraglutide
- Helps regulate appetite and food intake.
- Has established clinical evidence for weight management.
- Has well-documented prescribing and safety information.
Possible side effects and considerations
Common side effects include nausea, vomiting, diarrhea, and constipation. Liraglutide requires daily administration and generally produces less average weight loss than newer treatments in direct clinical comparisons. However, treatment selection also depends on eligibility, tolerability, availability, and individual preferences.
Semaglutide vs. Tirzepatide vs. Liraglutide: How Do They Compare?
Although these medications influence similar biological processes, they differ in their mechanisms, administration schedules, and clinical results.
| Medication | How it works | Administration | Clinical evidence |
| Semaglutide | Activates GLP-1 receptors | Weekly injection or daily oral tablet | Strong evidence for substantial weight loss |
| Tirzepatide | Activates GLP-1 and GIP receptors | Weekly injection | Greater average weight loss than injectable semaglutide in a direct trial |
| Liraglutide | Activates GLP-1 receptors | Daily injection | Effective, but generally less average weight loss than semaglutide in direct comparisons |
Which peptide works best for weight loss?
In a direct head-to-head trial, tirzepatide produced greater average weight loss than injectable semaglutide. In a separate trial, semaglutide produced greater average weight loss than liraglutide.
However, this does not mean everyone will achieve the same results.
Clinical outcomes depend on several factors, including the medication, dose, treatment duration, individual response, and accompanying lifestyle changes.
A healthcare provider can help determine which treatment is appropriate based on your medical history and weight-management needs.
What About Retatrutide and Other Peptides Being Studied for Weight Loss?
In addition to established medications, researchers are investigating several other peptides for their effects on weight management, metabolism, and body composition.
Some have produced promising early results, while others have limited clinical evidence in humans.
4. Retatrutide
Retatrutide is an investigational peptide-based medication designed to activate three hormone receptors:
- GLP-1
- GIP
- Glucagon
These pathways influence appetite, blood sugar regulation, and energy metabolism. Researchers are studying whether activating all three adds metabolic and weight-management benefits.
What does the research show?
In a phase 2 trial published in 2023, adults receiving the highest retatrutide dose lost an average of 24.2% of their body weight over 48 weeks.
Phase 3 results are now emerging. In May 2026, Eli Lilly announced topline results from TRIUMPH-1, a trial of 2,339 adults with obesity or overweight. Participants with severe obesity who took the highest doses lost up to about 30% of their body weight at 104 weeks. In July 2026, Lilly reported that retatrutide also met its weight-loss endpoints in TRIUMPH-2 and TRIUMPH-3, which enrolled adults with type 2 diabetes and with established cardiovascular disease, with weight loss of up to 22.6% at 80 weeks.
These are topline results announced by the manufacturer. They have not yet gone through full peer review and publication. They also come from different trials and patient populations than those used to evaluate semaglutide and tirzepatide, so the percentages should not be read as a direct head-to-head comparison.
Retatrutide is not FDA-approved. Lilly has said it plans to submit it for regulatory review in 2027, and its long-term safety and effectiveness are still being evaluated.
5. CJC-1295 and Ipamorelin
CJC-1295 and ipamorelin are peptides associated with growth hormone signaling. CJC-1295 is designed to stimulate growth hormone release through growth hormone-releasing hormone pathways. Ipamorelin stimulates growth hormone release by activating the ghrelin receptor. These peptides have attracted interest in discussions about body composition, recovery, and metabolism.
Can CJC-1295 and ipamorelin help with weight loss?
The interest comes partly from the relationship between growth hormone, fat metabolism, and lean body mass. However, research directly demonstrating meaningful, sustained weight loss from these peptides in humans remains limited.
While these substances have been studied for their effects on growth hormone pathways, further clinical research is needed to establish their effectiveness for weight management. Neither is FDA-approved as a weight-loss treatment.
6. AOD-9604
AOD-9604 is a modified fragment of human growth hormone that has been investigated for its potential effects on fat metabolism.
Researchers developed it to explore whether certain metabolic effects associated with growth hormone could be studied separately from its other biological functions.
What does the research show?
AOD-9604 has been investigated in human studies, including research related to obesity and fat metabolism. However, the available clinical findings have not established consistent, meaningful weight-loss benefits. Further research would be needed to determine whether it has a useful role in weight management. AOD-9604 is not yet FDA-approved for weight loss.
7. BPC-157
BPC-157 is an experimental peptide that has attracted research interest primarily in relation to tissue repair, inflammation, and recovery. Most of the available evidence comes from laboratory and animal studies.
Does BPC-157 help with weight loss?
BPC-157 is sometimes discussed alongside peptides used for body composition and general wellness. However, there is insufficient human clinical evidence to establish its effectiveness for weight loss. Its potential therapeutic applications remain an area of research, and it is not an FDA-approved weight-loss medication.
How Do Approved and Investigational Weight-Loss Peptides Compare?
Understanding the difference between established and investigational treatments can help put research findings into context.
| Peptide | Main research focus | Evidence for weight loss | FDA weight-loss approval |
| Semaglutide | Appetite and GLP-1 signaling | Strong clinical evidence | Yes, in approved formulations |
| Tirzepatide | GLP-1 and GIP signaling | Strong clinical evidence | Yes, in approved formulations |
| Liraglutide | Appetite and GLP-1 signaling | Established clinical evidence | Yes, in approved formulations |
| Retatrutide | GLP-1, GIP, and glucagon signaling | Phase 3 results announced, not yet approved | No |
| CJC-1295 | Growth hormone signaling | Insufficient direct human evidence for weight loss | No |
| Ipamorelin | Growth hormone signaling | Insufficient direct human evidence for weight loss | No |
| AOD-9604 | Fat metabolism | Inconclusive clinical evidence | No |
| BPC-157 | Tissue repair and recovery | Insufficient human evidence | No |
The strongest evidence for treating obesity currently comes from medications that have completed large clinical trials.
Other peptides may have interesting biological mechanisms, but their roles in weight management require further investigation.
Are Peptides for Weight Loss Safe?
Safety depends on the specific peptide, its formulation, the available research, and the individual’s medical history. Medications such as semaglutide, tirzepatide, and liraglutide have established safety information from clinical trials and ongoing medical use. However, they can still cause side effects and are not suitable for everyone.
Common Side Effects of GLP-1-Based Treatments
Some frequently reported side effects include:
- Nausea
- Vomiting
- Diarrhea
- Constipation
- Abdominal discomfort
- Reduced appetite
These symptoms often occur when treatment begins or the prescribed dose increases. Some patients experience mild symptoms, while others may require treatment adjustments.
Other Safety Considerations
Approved GLP-1-based weight-loss medications can carry warnings about pancreatitis, gallbladder problems, kidney injury related to dehydration, and serious gastrointestinal reactions.
Certain treatments also carry boxed warnings concerning thyroid C-cell tumors observed in rodents.
Medications with these warnings are contraindicated for patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
A healthcare provider should assess these considerations before recommending treatment.
What About Compounded Peptide Medications?
Some peptide-based medications can be prepared by compounding pharmacies under specific legal and medical circumstances. Compounded medications are not FDA-approved. They have not gone through the FDA’s premarket review for safety, effectiveness, or quality, and they are not the same as generic drugs.
Since the national shortages of semaglutide and tirzepatide ended, the rules for compounding them have tightened. The FDA has also stepped up enforcement against telehealth companies that market compounded GLP-1 products as equivalent to approved medications. It has reported dosing errors involving compounded semaglutide, including cases that required hospitalization.
If you’re considering a compounded medication, ask your provider:
- Whether an FDA-approved option is suitable for you
- Which pharmacy prepares the medication and how it is licensed
- How the dose is measured and how it will be administered
- What the product is, and is not, compared with the approved version
How Long Does It Take for Weight-Loss Peptides to Work?
The timeline depends on the treatment, prescribed dose, and individual response. Some people taking GLP-1-based medications notice changes in appetite relatively early. However, meaningful changes in body weight generally develop over weeks and months. Clinical trials frequently evaluate outcomes over periods lasting more than a year.
Several factors influence progress:
- The medication and prescribed dose.
- Starting weight and metabolic health.
- Individual response to treatment.
- Nutrition and physical activity.
- Treatment consistency.
- Other medical conditions.
For approved medications, providers often increase the dose gradually to improve tolerability. It’s also important to remember that clinical trial averages describe groups of participants, not guaranteed individual outcomes.
What Happens When You Stop Taking Weight-Loss Peptides?
Weight regain is possible after stopping medications that regulate appetite. This happens partly because the biological effects that helped reduce food intake may decrease after treatment ends. In an extension of a semaglutide clinical trial, researchers followed participants after they stopped taking the medication.
Over the following year, participants regained approximately two-thirds of the weight they had previously lost, on average. This does not mean everyone will experience the same amount of weight regain.
However, it shows why weight management may require a longer-term plan. Nutrition, physical activity, medical follow-up, and other health factors can remain important after medication is discontinued. Patients should discuss treatment duration and weight-maintenance strategies with their healthcare provider.
How Do You Choose the Right Peptide for Weight Loss?
Choosing a treatment involves more than comparing average weight-loss percentages. The appropriate option depends on your health, treatment eligibility, preferences, and goals.
1. Consider Your Medical History
Existing conditions, current medications, and family medical history may influence treatment suitability. A healthcare provider can identify potential contraindications and other factors that need attention.
2. Understand Your Weight-Management Goals
Some people are managing obesity alongside conditions such as high blood pressure, sleep apnea, or type 2 diabetes. Others may have previously tried different weight-management approaches without achieving lasting results. Your health goals help determine which treatment options deserve consideration.
3. Compare Treatment Requirements
Some medications require daily administration, while others use weekly injections. Cost, availability, follow-up requirements, and personal preferences may also affect treatment decisions.
4. Review the Evidence and Potential Risks
Look at what clinical research shows about effectiveness, safety, and treatment duration. An approved medication with extensive evidence may provide greater certainty about expected outcomes than an investigational treatment.
5. Plan for Long-Term Weight Management
Weight management extends beyond the initial treatment period. Discuss nutrition, physical activity, medical monitoring, and strategies for maintaining progress.
Exploring Medical Weight Loss in San Antonio
If you’re considering peptide-based medical weight loss, understanding your treatment options is a useful starting point. At Groov Wellness in San Antonio, the medical weight-loss program includes semaglutide and tirzepatide. The program focuses on individualized treatment planning, with medication selection and dosing determined through a provider evaluation. A consultation provides an opportunity to discuss your weight-management goals, medical history, and questions about available treatments.
Groov Wellness serves patients in San Antonio and nearby communities, including Helotes, The Dominion, and Shavano Park. Learn more about Groov Wellness’ medical weight-loss program or contact us to explore your options.
Which Peptides Have the Strongest Evidence for Weight Loss?
Semaglutide, tirzepatide, and liraglutide have established clinical evidence supporting their use for weight management in eligible patients.
Tirzepatide has produced greater average weight loss than injectable semaglutide in direct research, although individual results and treatment suitability vary.
Retatrutide, still investigational, has shown substantial weight loss in phase 3 trials announced in 2026, while peptides such as CJC-1295, ipamorelin, AOD-9604, and BPC-157 require more evidence to establish their roles in weight management.
The most appropriate option depends on your health, treatment goals, and a qualified provider’s assessment.
References
- Wilding JPH, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. Read the study.
- Aronne LJ, et al. (2025). Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine. Read the study.
- Rubino DM, et al. (2022). Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity. JAMA. Read the study.
- Jastreboff AM, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity. New England Journal of Medicine. Read the study.
- Wilding JPH, et al. (2022). Weight Regain and Cardiometabolic Effects After Withdrawal of Semaglutide. Diabetes, Obesity and Metabolism. Read the study.
- U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. Read FDA guidance.
- U.S. Food and Drug Administration. Dosing Errors Associated With Compounded Injectable Semaglutide Products. Read FDA safety communication.
